Search results
GlycoMimetics (NASDAQ:GLYC) Downgraded to Equal Weight at Capital One Financial
ETF DAILY NEWS· 5 days agoCapital One Financial lowered shares of GlycoMimetics (NASDAQ:GLYC – Free Report) from an overweight rating to an equal weight rating in a research report sent to investors on Monday morning ...
Earnings call: Kura Oncology reports on ziftomenib's progress By Investing.com
Investing.com· 6 days agoZiftomenib has received Breakthrough Therapy designation from the FDA for the treatment of...
Exxon hit with $725.5 million verdict over mechanic's leukemia diagnosis
Reuters· 2 days ago, opens new tab to pay $725.5 million to a former mechanic who claimed toxic chemicals in the...
Danbury High runner who was on death bed with cancer graduates from Sacred Heart: 'Very determined'
The News-Times· 2 days agoIn May 2019, 21-year-old Alex Chakar was diagnosed with acute myeloid leukemia and within a few...
GlycoMimetics downgraded after Phase 3 trial fails to meet endpoint By Investing.com
Investing.com· 6 days agoGlycoMimetics' uproleselan, a drug candidate for treating relapsed or refractory acute myeloid ...
Exxon ordered to pay $725M to mechanic who claimed toxic chemicals caused his cancer
New York Post· 2 days agoThe 67-year-old former mechanic said in his 2020 lawsuit that he used petroleum products to clean...
Analysts Offer Predictions for Actinium Pharmaceuticals, Inc.’s Q2 2024 Earnings (NYSEAMERICAN:ATNM)
ETF DAILY NEWS· 6 days agoActinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Free Report) – Research analysts at B. Riley issued their Q2 2024 earnings per share estimates for Actinium Pharmaceuticals in a research ...
Earnings call: Kura Oncology reports on ziftomenib's progress
Investing.com· 7 days agoZiftomenib has received Breakthrough Therapy designation from the FDA for the treatment of...
Jury Says Exxon Mobil Must Pay $725 Million to Former Mechanic Who Developed Cancer
The Wall Street Journal· 2 days agoA Pennsylvania jury found Exxon Mobil liable for about $725 million in compensatory damages to a...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio,...
Benzinga· 4 hours agoNEW YORK, May 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE). Such investors are advised to